Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Huan Wang, Xiaoyun Mao, Huan Wang, Xiaoyun Mao

Abstract

Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for downstaging the primary tumor in the breast and the metastatic axillary lymph node. Accurate evaluations of the response to neoadjuvant chemotherapy provide important information on the impact of systemic therapies on breast cancer biology, prognosis, and guidance for further therapy. Moreover, pathologic complete response is a validated and valuable surrogate prognostic factor of survival after therapy. Evaluations of neoadjuvant chemotherapy response are very important in clinical work and basic research. In this review, we will elaborate on evaluations of the efficacy of neoadjuvant chemotherapy in breast cancer and provide a clinical evaluation procedure for neoadjuvant chemotherapy.

Keywords: breast cancer; evaluations of response; neoadjuvant chemotherapy.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2020 Wang and Mao.

References

    1. Schegerin M, Tosteson ANA, Kaufman PA, Paulsen KD, Pogue BW. Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective. Breast Cancer Res Treat. 2009;114(3):537–547. doi:10.1007/s10549-008-0025-2
    1. Charfare H, Limongelli S, Purushotham A. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005;92(1):14–23. doi:10.1002/bjs.4840
    1. Costa SD, Loibl S, Kaufmann M. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2010;28(1):83–91. doi:10.1200/JCO.2009.23.5101
    1. Katz SJ. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. Obstet Gynecol Surv. 2009;65(14):1551–1556.
    1. Buchholz TA, Mittendorf EA, Hunt KK. Surgical considerations after neoadjuvant chemotherapy: breast conservation therapy. J Natl Cancer Inst Monogr. 2015;51:51.
    1. Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(15):1747–1749. doi:10.1200/JCO.2011.41.3161
    1. Vaidya JS, Massarut S, Vaidya HJ, et al. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ. 2018; 360:j5913. doi:10.1136/bmj.j5913
    1. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159. doi:10.1056/NEJMoa1612645
    1. von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31(29):3623–3630. doi:10.1200/JCO.2012.45.0940
    1. Spring LM, Fell G, Arfe A, et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020. doi:10.1158/1078-0432.CCR-19-3492
    1. Krishnan Y, Alawadhi SA, Sreedharan PS, Gopal M, Thuruthel S. Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years. Ann Saudi Med. 2013;33(5):443–450. doi:10.5144/0256-4947.2013.443
    1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216. doi:10.1093/jnci/92.3.205
    1. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.081
    1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214. doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>;2-6
    1. Schwartz LH, Seymour L, Litière S, et al. RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer. 2016;62:138–145. doi:10.1016/j.ejca.2016.03.082
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
    1. Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2017;14(3):187–192. doi:10.1038/nrclinonc.2016.195
    1. Muenzel D, Engels HP, Bruegel M, Kehl V, Rummeny EJ, Metz S. Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. Radiol Oncol. 2012;46(1):8–18. doi:10.2478/v10019-012-0009-z
    1. Fukada I, Araki K, Kobayashi K, et al. Pattern of tumor shrinkage during neoadjuvant chemotherapy is associated with prognosis in low-grade luminal early breast cancer. Radiology. 2018;286(1):49–57. doi:10.1148/radiol.2017161548
    1. Li M, Xu B, Shao Y, Liu H, Du B, Yuan J. Magnetic resonance imaging patterns of tumor regression in breast cancer patients after neo-adjuvant chemotherapy, and an analysis of the influencing factors. Breast J. 2017;23(6):656–662. doi:10.1111/tbj.12811
    1. Eom HJ, Cha JH, Choi WJ, Chae EY, Shin HJ, Kim HH. Predictive clinicopathologic and dynamic contrast-enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple-negative breast cancer. AJR Am J Roentgenol. 2017;208(6):W225–W230. doi:10.2214/AJR.16.17125
    1. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy–results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663–672. doi:10.1148/radiol.12110748
    1. Rauch GM, Adrada BE, Kuerer HM, van la Parra RF, Leung JW, Yang WT. Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer. AJR Am J Roentgenol. 2017;208(2):290–299. doi:10.2214/AJR.16.17223
    1. Li H, Yao L, Jin P, et al. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast (Edinburgh, Scotland). 2018;40:106–115. doi:10.1016/j.breast.2018.04.018
    1. van der Noordaa MEM, van Duijnhoven FH, Straver ME, et al. Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET/CT and the MARI procedure. Ann Surg Oncol. 2018;25(6):1512–1520. doi:10.1245/s10434-018-6404-y
    1. Christin OL, Kuten J, Even-Sapir E, Klausner J, Menes TS. Node positive breast cancer: concordance between baseline PET/CT and sentinel node assessment after neoadjuvant therapy. Surg Oncol. 2019;30:1–5. doi:10.1016/j.suronc.2019.05.006
    1. Thomassin-Naggara I, Tardivon A, Chopier J. Standardized diagnosis and reporting of breast cancer. Diagn Interv Imaging. 2014;95(7–8):759–766. doi:10.1016/j.diii.2014.06.006
    1. Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology. 2017;285(2):358–375. doi:10.1148/radiol.2017170180
    1. Kim YS, Chang JM, Moon HG, Lee J, Shin SU, Moon WK. Residual mammographic microcalcifications and enhancing lesions on MRI after neoadjuvant systemic chemotherapy for locally advanced breast cancer: correlation with histopathologic residual tumor size. Ann Surg Oncol. 2016;23(4):1135–1142. doi:10.1245/s10434-015-4993-2
    1. Evans A, Whelehan P, Thompson A, et al. Prediction of pathological complete response to neoadjuvant chemotherapy for primary breast cancer comparing interim ultrasound, shear wave elastography and MRI. Ultraschall Med. 2018;39(4):422–431. doi:10.1055/s-0043-111589
    1. Piotrzkowska-Wróblewska H, Dobruch-Sobczak K, Klimonda Z, et al. Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter. PLoS One. 2019;14(3):e0213749. doi:10.1371/journal.pone.0213749
    1. Mattingly AE, Mooney B, Lin HY, et al. Magnetic resonance imaging for axillary breast cancer metastasis in the neoadjuvant setting: a prospective study. Clin Breast Cancer. 2017;17(3):180–187. doi:10.1016/j.clbc.2016.11.004
    1. Rajan R, Poniecka A, Smith TL, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer. 2004;100(7):1365–1373. doi:10.1002/cncr.20134
    1. Baumgartner A, Tausch C, Hosch S, et al. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast (Edinburgh, Scotland). 2018;39:19–23. doi:10.1016/j.breast.2018.02.028
    1. Marinovich ML, Houssami N, Macaskill P, von Minckwitz G, Blohmer JU, Irwig L. Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer. Int J Cancer. 2015;136(11):2730–2737. doi:10.1002/ijc.29323
    1. Abedi M, Farrokh D, Shandiz Homaei F, et al. The validity of MRI in evaluation of tumor response to neoadjuvant chemotherapy in locally advanced breast cancer. Iran J Cancer Prev. 2013;6(1):28–35.
    1. Choi WJ, Kim HH, Cha JH, Shin HJ, Chae EY. Comparison of pathologic response evaluation systems after neoadjuvant chemotherapy in breast cancers: correlation with computer-aided diagnosis of MRI features. AJR Am J Roentgenol. 2019;213(4):944–952. doi:10.2214/AJR.18.21016
    1. Taydaş O, Durhan G, Akpınar MG, Demirkazık FB. Comparison of MRI and US in tumor size evaluation of breast cancer patients receiving neoadjuvant chemotherapy. Eur J Breast Health. 2019;15(2):119–124. doi:10.5152/ejbh.2019.4547
    1. Goorts B, Dreuning KMA, Houwers JB, et al. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer. Breast Cancer Res. 2018;20(1):34. doi:10.1186/s13058-018-0950-x
    1. Lobbes MB, Lalji UC, Nelemans PJ, et al. The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI. J Cancer. 2015;6(2):144–150. doi:10.7150/jca.10705
    1. Türkbey B, Thomasson D, Pang Y, Bernardo M, Choyke PL. The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol. 2010;16(3):186–192. doi:10.4261/1305-3825.DIR.2537-08.1
    1. Kim Y, Kim SH, Lee HW, et al. Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer. Magn Reson Imaging. 2018;48:27–33. doi:10.1016/j.mri.2017.12.018
    1. Newitt DC, Zhang Z, Gibbs JE, et al. Test-retest repeatability and reproducibility of ADC measures by breast DWI: results from the ACRIN 6698 trial. J Magn Reson Imaging. 2019;49(6):1617–1628. doi:10.1002/jmri.26539
    1. Tahmassebi A, Wengert GJ, Helbich TH, et al. Impact of machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy and survival outcomes in breast cancer patients. Invest Radiol. 2019;54(2):110–117. doi:10.1097/RLI.0000000000000518
    1. You C, Li J, Zhi W, et al. The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer. J Transl Med. 2019;17(1):182. doi:10.1186/s12967-019-1911-6
    1. Che S, Zhao X, Ou Y, et al. Role of the intravoxel incoherent motion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer. Medicine. 2016;95(4):e2420. doi:10.1097/MD.0000000000002420
    1. Cho GY, Moy L, Kim SG, et al. Evaluation of breast cancer using intravoxel incoherent motion (IVIM) histogram analysis: comparison with malignant status, histological subtype, and molecular prognostic factors. Eur Radiol. 2016;26(8):2547–2558. doi:10.1007/s00330-015-4087-3
    1. Mao X, Zou X, Yu N, Jiang X, Du J. Quantitative evaluation of intravoxel incoherent motion diffusion-weighted imaging (IVIM) for differential diagnosis and grading prediction of benign and malignant breast lesions. Medicine. 2018;97(26):e11109. doi:10.1097/MD.0000000000011109
    1. Zhang D, Zhang Q, Suo S, et al. Apparent diffusion coefficient measurement in luminal breast cancer: will tumour shrinkage patterns affect its efficacy of evaluating the pathological response? Clin Radiol. 2018;73(10):909.e907–909.e914. doi:10.1016/j.crad.2018.05.026
    1. Moy L. Do tumor shrinkage patterns at breast MR imaging predict survival? Radiology. 2018;286(1):58–59. doi:10.1148/radiol.2017171975
    1. Tomida K, Ishida M, Umeda T, et al. Magnetic resonance imaging shrinkage patterns following neoadjuvant chemotherapy for breast carcinomas with an emphasis on the radiopathological correlations. Mol clin oncol. 2014;2(5):783–788. doi:10.3892/mco.2014.333
    1. Negrão EMS, Souza JA, Marques EF, Bitencourt AGV. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy. Eur J Radiol. 2019;120:108701. doi:10.1016/j.ejrad.2019.108701
    1. Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, et al. 18F-FDG PET/CT in breast cancer: evidence-based recommendations in initial staging. Tumour Biol. 2017;39(10):1010428317728285. doi:10.1177/1010428317728285
    1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1(Suppl 1):122s–150s. doi:10.2967/jnumed.108.057307
    1. Sidaway P. Early PET response predicts complete response. Nat Rev Clin Oncol. 2019;16(4):208. doi:10.1038/s41571-019-0189-1
    1. Hieken TJ, Boughey JC, Jones KN, Shah SS, Glazebrook KN. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20(10):3199–3204. doi:10.1245/s10434-013-3118-z
    1. Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34(12):1915–1924. doi:10.1007/s00259-007-0459-5
    1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–2493. doi:10.1200/JCO.1997.15.7.2483
    1. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast (Edinburgh, Scotland). 2003;12(5):320–327.
    1. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009;133(4):633–642.
    1. Arkhypchuk AI, Santoni MP, Ott S. Cascade reactions forming highly substituted, conjugated phospholes and 1,2-oxaphospholes. Angew Chem Int Ed Engl. 2012;51(31):7776–7780. doi:10.1002/anie.201202153
    1. Penault-Llorca F, Abrial C, Raoelfils I, et al. Comparison of the prognostic significance of Chevallier and Sataloff’s pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008;39(8):1221–1228. doi:10.1016/j.humpath.2007.11.019
    1. Shien T, Shimizu C, Seki K, et al. Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. Breast Cancer Res Treat. 2009;113(2):307–313. doi:10.1007/s10549-008-9935-2
    1. Delage E, Ruelland E, Zachowski A, Puyaubert J. Eat in or take away? How phosphatidylinositol 4-kinases feed the phospholipase C pathway with substrate. Plant Signal Behav. 2012;7(9):1197–1199. doi:10.4161/psb.21305
    1. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer. 2003;88(9):1339–1345. doi:10.1038/sj.bjc.6600916
    1. Asano Y, Kashiwagi S, Goto W, et al. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. BMC Cancer. 2017;17(1):888. doi:10.1186/s12885-017-3927-8
    1. Lee SM, Bae SK, Kim TH, et al. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy. Clin Nucl Med. 2014;39(10):882–886. doi:10.1097/RLU.0000000000000531
    1. Sheri A, Smith IE, Johnston SR, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol. 2015;26(1):75–80. doi:10.1093/annonc/mdu508
    1. Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35(10):1049–1060. doi:10.1200/JCO.2015.63.1010
    1. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–4422. doi:10.1200/JCO.2007.10.6823
    1. Abrial C, Thivat E, Tacca O, et al. Measurement of residual disease after neoadjuvant chemotherapy. J Clin Oncol. 2008;26(18):3094;author reply 3095. doi:10.1200/JCO.2008.16.7817
    1. Marmé F, Lederer B, Blohmer JU, et al. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2016;53:65–74. doi:10.1016/j.ejca.2015.09.022
    1. Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29(15):1956–1962. doi:10.1200/JCO.2010.31.8469
    1. Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244(3):464–470. doi:10.1097/01.sla.0000234897.38950.5c
    1. Horii R, Akiyama F. Histological assessment of therapeutic response in breast cancer. Breast Cancer (Tokyo, Japan). 2016;23(4):540–545. doi:10.1007/s12282-013-0499-6
    1. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16(3):223–228. doi:10.1097/00000421-199306000-00006
    1. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180(3):297–306.
    1. Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005;94(3):255–263. doi:10.1007/s10549-005-9008-8
    1. Park J, Chae EY, Cha JH, et al. Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy. Eur J Radiol. 2018;108:261–268. doi:10.1016/j.ejrad.2018.09.032
    1. Lombard I, Vincent-Salomon A, Validire P, et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol. 1998;16(8):2613–2619. doi:10.1200/JCO.1998.16.8.2613
    1. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165–4174. doi:10.1200/JCO.2003.12.005
    1. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13(3):547–552. doi:10.1200/JCO.1995.13.3.547
    1. Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the national cancer data base (NCDB). Ann Surg. 2018;268(4):591–601. doi:10.1097/SLA.0000000000002953
    1. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–1078. doi:10.1200/JCO.2015.64.0094
    1. Racz JM, Caudle AS. Sentinel node lymph node surgery after neoadjuvant therapy: principles and techniques. Ann Surg Oncol. 2019;26(10):3040–3045. doi:10.1245/s10434-019-07591-6
    1. Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152(7):665–670. doi:10.1001/jamasurg.2017.0562
    1. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; Updated November 27, 2017. Available from: . Accessed July17, 2018.
    1. Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J. Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res. 2012;2(2):111–116. doi:10.4103/2229-516X.106353
    1. Kumar S, Badhe BA, Krishnan KM, Sagili H. Study of tumour cellularity in locally advanced breast carcinoma on neo-adjuvant chemotherapy. J Clin Diagn Res. 2014;8(4):Fc09–Fc13. doi:10.7860/JCDR/2014/7594.4283
    1. Atuegwu NC, Arlinghaus LR, Li X, et al. Parameterizing the logistic model of tumor growth by DW-MRI and DCE-MRI data to predict treatment response and changes in breast cancer cellularity during neoadjuvant chemotherapy. Transl Oncol. 2013;6(3):256–264. doi:10.1593/tlo.13130
    1. Khanna AK, Saxena SK, Khanna S, Kumar A. Histopathological changes following anterior chemotherapy in advanced breast cancer. Indian J Cancer. 1990;27(2):109–115.
    1. Aktepe F, Kapucuoğlu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology. 1996;29(1):63–67. doi:10.1046/j.1365-2559.1996.d01-485.x

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit